31st May 2022
Monkeypox articles for use
This additional information is included as part of a press release labeling system introduced by the Academy of Medical Sciences and Science Media Centre. For more details click here.
Monkeypox has been known to be in existence in humans since the 1970s. Therefore, fortunately, there is already a wealth of information and research on this virus. You can access a vast array of research on the topic for your articles by signing up for our Press Pass service.
The Press Pass will provide you immediate online access to over 4 million peer-reviewed academic research articles, including on anything associated with this new potential endemic.
For now, please find our top recommended articles to start with:
The vaccine, Tecovirimat, shows broad efficacy against orthopoxviruses (such as monkeypox) in vitro and in vivo and could be developed for use against emerging orthopoxvirus diseases such as monkeypox, vaccination-associated adverse events, and side effects of vaccinia oncolytic virus therapy.
Tecovirimat (TPOXX®; ST-246) was approved for the treatment of symptomatic smallpox by the USFDA in July of 2018 and has been stockpiled by the US government for use in a smallpox outbreak.
The smallpox vaccine treats monkeypox. However, a ‘covid style’ roll-out is unlikely. The tactic will likely be to vaccinate close contacts of those infected – which is how smallpox was eradicated in India. This article models how the vaccine could be delivered on mass.
ACAM2000™ is one of the new generation of smallpox vaccines, approved for use against monkeypox. The U.S. Food and Drug Administration (FDA) approved ACAM2000 in August 2007. By February 2008, it replaced Dryvax for all smallpox vaccinations. As of 2010, there were over 200 million doses manufactured for the U.S. Strategic National Stockpile.
This article explores the benefits of ACAM2000.
Experts witness a rise in cases in Africa, back in 2020. They state that epidemiological and basic research to unravel the source and mode of transmission of the monkeypox virus and the true incidence of this disease demands greater attention.
A review of laboratory and field studies, which examines the susceptibility of various animal’s monkeypox virus infections, and the competence of various species to serve as reservoirs or transmission hosts. The article also focuses on where research would be best targeted to prevent the virus.
Monkeypox has been witnessed in dogs previously.
In 2003, an outbreak in the United States associated with legally imported African ‘pocket pets’ led to 72 suspected human cases in six states. Eighteen persons were hospitalized, some because of the potential for human-to-human spread. Interestingly, a number of the cases were veterinarians or veterinary technicians exposed while treating ill pets, highlighting the potential occupational risk. The majority of patients had direct or close contact with prairie dogs. These prairie dogs were infected by close contact with imported animals (including rope squirrels, tree squirrels, Gambian giant rats, brushtail porcupines and dormice) from Ghana shipped to a distributor in Texas
Why aren’t there antiviral treatments against smallpox and related viruses, such as monkeypox yet? This article discusses how the development of antiviral drugs for the treatment of diseases where human clinical trials that measure compound efficacy are either unethical or are not feasible – which, therefore pose a challenge for drug development.
Preparedness for monkeypox couldn’t be more distant to when covid struck, and that’s thanks to the smallpox vaccine. This article explores the history of smallpox, vaccination, and the scientist influential in eradicating the virus, Edward Jenner
Misleading monkeypox information in the media, and social media, could further fuel public anxiety – as was the case with Ebola in 2014. This research examines the variety of coverage during that crisis eight years ago.